These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1202718)

  • 1. Effect of hormone therapy on immune response in patients with prostatic cancer.
    Guinan PD; Ablin RJ; Nourkayhan S; Bruns GR; Bush IM
    Urology; 1975 Dec; 6(6):693-6. PubMed ID: 1202718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy.
    Kane RD; Mickey DD; Paulson DF
    Urology; 1976 Dec; 8(6):559-62. PubMed ID: 997050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostatic carcinoma cured with hormonal treatment. A report of two cases.
    Johansson S; Ljunggren E
    Scand J Urol Nephrol; 1981; 15(3):321-2. PubMed ID: 7323757
    [No Abstract]   [Full Text] [Related]  

  • 4. [Results of the treatment of prostatic cancer (author's transl)].
    Takayasu H; Ogawa A; Koiso K; Komine Y; Ishii Y
    Nihon Hinyokika Gakkai Zasshi; 1978 Apr; 69(4):426-35. PubMed ID: 671900
    [No Abstract]   [Full Text] [Related]  

  • 5. Urethral obstruction secondary to carcinoma of prostate: response to endocrine treatment.
    Varenhorst E; Alund G
    Urology; 1985 Apr; 25(4):354-6. PubMed ID: 3157256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine and immune responses to resistance training in prostate cancer patients.
    Galvão DA; Nosaka K; Taaffe DR; Peake J; Spry N; Suzuki K; Yamaya K; McGuigan MR; Kristjanson LJ; Newton RU
    Prostate Cancer Prostatic Dis; 2008; 11(2):160-5. PubMed ID: 17637762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of estrogen on tumor-associated immunity in patients with adenocarcinoma of the prostate.
    Ablin RJ; Bhatti RA; Guinan PD
    Cancer Res; 1978 Nov; 38(11 Pt 1):3702-6. PubMed ID: 698929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sex hormones on immunity.
    Ablin RJ
    Clin Oncol; 1978 Dec; 4(4):379-82. PubMed ID: 729227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal treatment in prostate cancer.
    Zbranca E; Preda C
    Endocrinologie; 1991; 29(1-2):91-7. PubMed ID: 1803495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of BCG upon functional and phenotypic immune markers in rats bearing the Dunning R3327 MAT-LyLu prostatic adenocarcinoma.
    Rubenstein M; Shaw MW; Dubin A; McKiel CF; Guinan PD
    Immunopharmacol Immunotoxicol; 1988; 10(4):579-96. PubMed ID: 2977608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostate antigen as a tumor marker of prostate cancer. (1) Changes of prostate antigen values during anti-androgen therapy].
    Kuriyama M; Takeuchi T; Okano M; Fujimoto Y; Fujihiro S; Nishiura T; Murphy GP; Chu TM
    Nihon Gan Chiryo Gakkai Shi; 1984 Aug; 19(7):1481-7. PubMed ID: 6084037
    [No Abstract]   [Full Text] [Related]  

  • 12. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
    Lundgren R; Nordle O; Josefsson K
    J Urol; 1995 May; 153(5):1580-6. PubMed ID: 7714978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Thyroid hormones in metastasizing prostate cancer treated with polyestradiol phosphate].
    Dunzendorfer U; Schulz H
    Z Urol Nephrol; 1982 Jul; 75(7):493-500. PubMed ID: 6183845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer.
    Ahmann FR; Schifman RB
    J Urol; 1987 Mar; 137(3):431-4. PubMed ID: 2434667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hormone therapy for prostatic neoplasms--(1)prognosis, cause of death and estrogen therapy].
    Katayama K; Momose G
    Horumon To Rinsho; 1975 Jul; 23(7):697-702. PubMed ID: 1170990
    [No Abstract]   [Full Text] [Related]  

  • 16. [Aspects for hormone therapy in prostate cancer].
    Gorski J; Böhm WD; Kelly LU
    Z Urol Nephrol; 1981 Sep; 74(9):635-41. PubMed ID: 7314984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
    Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
    Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
    Aro J; Ruutu M; Juusela H; Hansson E; Permi J
    Ann Chir Gynaecol Suppl; 1993; 206():5-8. PubMed ID: 8291869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haematological variables in prostatic carcinoma patients.
    Geenen RW; Delaere KP; van Wersch JW
    Acta Urol Belg; 1996 Sep; 64(3):21-6. PubMed ID: 8946777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prostatic adenocarcinoma showing features of endometrioid and mucinous carcinomas: a case report].
    Nishimura K; Higashino M; Hara T; Oka T
    Hinyokika Kiyo; 1995 Oct; 41(10):805-7. PubMed ID: 8533679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.